{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82","upperLimit":"100","value":"92.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate.","groups":[{"description":"This is a subset of all patients enrolled. It is not a specific treatment arm.","id":"OG000","title":"Patients With High Risk of CNS Relapse"}],"paramType":"NUMBER","populationDescription":"Patients meeting the following high risk CNS Relapse criteria: white cell blood cell count at diagnosis more than 100,000; Philadelphia Chromosome Positive; CNS 3 at diagnosis; T-Lineage with white blood cell count more than 50,000.","reportingStatus":"POSTED","timeFrame":"Median follow up time (range) 4.5 (1 to 7.8) years","title":"Continuous Complete Remission Since Week 56 Therapy.","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}